<DOC>
	<DOCNO>NCT00168753</DOCNO>
	<brief_summary>To evaluate safety treat subject 12 additional dos alefacept .</brief_summary>
	<brief_title>Community Based Trial AMEVIVE®</brief_title>
	<detailed_description>Male female subject least 18 year age moderate severe plaque psoriasis treat 12 week alefacept 15 mg IM achieve desired response . Dosing Groups : Subjects receive either 4 , 8 , 12 dos alefacept 15 mg IM weekly immediately ( within 14 day ) follow standard 12-dose course AMEVIVE® 15 mg IM . Determination number dos base physician qualitative assessment week 4 8 .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>1 . Must give write informed consent . 2 . Must moderate , moderately severe severe chronic plaque psoriasis determine investigator prior initial treatment ( baseline ) AMEVIVE . 3 . Must 18 year age old . 4 . Must complete standard 12week course AMEVIVE receive least 10 dos . 5 . Response current AMEVIVE therapy must less desired response determine physician , subject residual psoriasis must present . 1 . Female subject postmenopausal least 1 year , surgically sterile , willing practice effective contraception study . 2 . Nursing mother , pregnant woman , woman plan become pregnant 3 . Current enrollment investigational study subject receive type drug , biologic , nondrug therapy . 4 . Treatment another investigational drug , approve therapy investigational use , within 3 month investigational drug administration . 5 . Treatment systemic retinoids , systemic steroid , methotrexate , cyclosporine , azathioprine , thioguanine , etanercept , efalizumab , infliximab , adalimumab mycophenolate mofetil systemic immunosuppressant agent within 4 week investigational drug administration . 6 . Treatment Ultraviolet B ( UVB ) phototherapy Psoralen + Ultraviolet A ( PUVA ) , within 4 week investigational drug administration . 7 . Serious local infection ( e.g. , cellulitis , abscess ) systemic infection ( e.g. , pneumonia , septicemia ) within 3 month prior first dose investigational drug . 8 . History &gt; 3 cutaneous squamous cell carcinoma systemic malignancy . 9 . Skin lesions suspicious malignancy . 10 . Known HIV , viral hepatitis , tuberculosis infection . 11 . History severe allergic anaphylactic reaction . 12 . ALT AST great three time upper limit normal . 13 . Significantly abnormal hematology ( hemoglobin , hematocrit , platelet , white blood cell ) , determine investigator . 14 . CD4+ T lymphocyte count screen visit le 250 cells/mm3 . 15 . Known hypersensitivity AMEVIVE component . 16 . Subject 's inability comply study requirement .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Extended dosing</keyword>
	<keyword>alefacept</keyword>
</DOC>